Clin Pain.  2023 Dec;22(2):104-114. 10.35827/cp.2023.22.2.104.

Safety and Effectiveness of Repeated Treatment of Dodium Polynucleotide in Knee Osteoarthritis

• Kim Wh
• Song Ys
• Ryu Hk
• Park Jh
• Kim Kj
• Son In

• KMID: 2550412
• DOI: http://doi.org/10.35827/cp.2023.22.2.104

Abstract

Objective
The objective of this study is to assess the efficacy and safety of repeated sodium polynucleotide (Conjuran ^Ⓡ ) treatments in patients with knee osteoarthritis. Methods: The study was conducted by retrospectively examining 45 patients who repeated the treatment course of 5 injections of Conjuran ^Ⓡ twice within 6 months. For each course, pain reduction by the change of 100-mm Weight-Bearing-Pain Visual-Analog-Scale was compared with before administration until 6 months after administration. Improvement by Clinical Global Impression (CGI) and Patient Global Impression (PGI) were also investigated, as well as adverse reactions.
Results
Pain analysis after administration of Conjuran ^Ⓡ confirmed that VAS decreased by 51.6% until 6 months (p＜0.001), and after that the effect was lost and was repeat for the 2 ^nd course. In the 2 ^nd , VAS continued to decrease by 58.7% compared to before the 1 ^st course (p＜0.001). Analysis of CGI, 88.9% of patients improved after the 1 ^st and 84.4% of patients improved after the 2 ^nd . In the PGI results, symptoms improved in 86.7% of patients after the 1 ^st and 82.2% after the 2 ^nd . No significant adverse event was reported.
Conclusion
The safety and efficacy results of patients receiving Conjuran ^Ⓡ for 2 ^nd treatment courses were similar to those for 1 ^st treatment course. In addition, the effect lasts for up to 6 months after administration, and the pain reduction effect is lost thereafter, so it is recommended to apply it at 6-month intervals if additional treatment is needed. Conjuran ^Ⓡ is an intra-articular injection that is effective in reducing knee pain and can be used repeatedly without adverse reactions.

Keyword

Knee osteoarthritis; Intra-articular injection; Sodium polynucleotide; Retrospective study; Clinical study